Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2009; postbronchodilator FEV1/FVC \< 70%, and postbronchodilator FEV1 ≥ 30% and \< 80% predicted~* Current or former cigarette smokers~Exclusion Criteria:~* Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit~* Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1~* Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness~* History or presence of asthma verified from medical records~* Chronic use of oxygen therapy greater than or equal to 15 hours per day~* Patient with uncontrolled infection due to HIV and/or active hepatitis~* Patients with a history of hypersensitivity reaction to inhaled anticholinergics~* Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aclidinium bromide dose, inhaled, for 12 weeks of treatment
- 2 (Type: EXPERIMENTAL): Aclidinium bromide dose, inhaled, for 12 weeks of treatment
- 3 (Type: PLACEBO_COMPARATOR): Inhaled placebo for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).